Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

2
Player Avatar avatar2005 (< 20) Submitted: 3/28/2007 11:06:19 PM : Outperform Start Price: $5.22 NABI Score: -67.71

Company's got alot of potential on the bench right now...anyone of which could be at least a double!

Featured Broker Partners


Advertisement